Kas Thomas writes: "The latest sales figures are out, and they show that in Q4 of 2012 the best-selling drug in the U.S., in terms of dollar volume, is Abilify, an atypical antipsychotic that's now widely prescribed as an adjunct for depression and other ills. How did it get to be No. 1? Largely through illegal sales tactics. In 2007, Bristol-Myers Squibb paid $515 million in a settlement with the U.S. government based on Justice Department findings that BMS paid doctors (and flew them to resorts) to prescribe the drug for off-label as well as on-label uses, among other marketing shenanigans (described at http://www.justice.gov/opa/pr/2007/September/07_civ_782.html)."